603127 昭衍新药
已收盘 01-09 15:00:00
资讯
新帖
简况
港股异动 | 昭衍新药(06127)涨超7% 近一月股价累涨近六成 公司有望受益猴价公允价值收益
智通财经 · 31分钟前
港股异动 | 昭衍新药(06127)涨超7% 近一月股价累涨近六成 公司有望受益猴价公允价值收益
港股异动 | 昭衍新药(06127)再涨超4% 实验猴供需缺口或不断拉大 公司拥有优质稀缺实验猴资源
智通财经 · 01-08 10:59
港股异动 | 昭衍新药(06127)再涨超4% 实验猴供需缺口或不断拉大 公司拥有优质稀缺实验猴资源
昭衍新药（603127）披露员工持股计划回购股份注销实施公告，1月6日股价下跌0.16%
证券之星 · 01-06 22:09
昭衍新药（603127）披露员工持股计划回购股份注销实施公告，1月6日股价下跌0.16%
昭衍新药（603127）披露H股及A股股本无变动情况，1月5日股价上涨10.0%
证券之星 · 01-05
昭衍新药（603127）披露H股及A股股本无变动情况，1月5日股价上涨10.0%
异动快报：昭衍新药（603127）1月5日10点53分触及涨停板
证券之星 · 01-05
异动快报：昭衍新药（603127）1月5日10点53分触及涨停板
港股医药股走强 昭衍新药涨近10%
南方财经网 · 01-05
港股医药股走强 昭衍新药涨近10%
每周股票复盘：昭衍新药（603127）实控人周志文拟减持不超1.99873%
证券之星 · 01-02
每周股票复盘：昭衍新药（603127）实控人周志文拟减持不超1.99873%
12月30日昭衍新药跌6.20%，广发小盘LOF基金重仓该股
证券之星 · 2025-12-30
12月30日昭衍新药跌6.20%，广发小盘LOF基金重仓该股
港股创新药板块午后持续走弱，昭衍新药跌超7%
每日经济新闻 · 2025-12-30
港股创新药板块午后持续走弱，昭衍新药跌超7%
昭衍新药实控人之一周志文计划减持不超近2%公司股份
财中社 · 2025-12-29
昭衍新药实控人之一周志文计划减持不超近2%公司股份
“顶流”刘格菘年内两度卸任 广发主动权益基金三年业绩之殇
市场资讯 · 2025-12-25
“顶流”刘格菘年内两度卸任 广发主动权益基金三年业绩之殇
港股异动 | 昭衍新药(06127)涨超5% 上游实验猴供给端紧张 公允价值变动有望贡献利润
智通财经 · 2025-12-23
港股异动 | 昭衍新药(06127)涨超5% 上游实验猴供给端紧张 公允价值变动有望贡献利润
港股异动 | CRO概念股承压走低 康龙化成(03759)跌超4% 昭衍新药(06127)跌超3%
智通财经 · 2025-12-22
港股异动 | CRO概念股承压走低 康龙化成(03759)跌超4% 昭衍新药(06127)跌超3%
昭衍新药：公司具备OECD的GLP认证资质
证券日报 · 2025-12-17
昭衍新药：公司具备OECD的GLP认证资质
港股异动 | 昭衍新药(06127)涨超8% 实验猴价格近期上行 机构料供需偏紧状态或将维持
智通财经 · 2025-12-17
港股异动 | 昭衍新药(06127)涨超8% 实验猴价格近期上行 机构料供需偏紧状态或将维持
昭衍新药午前涨超4% 本月股价已累计涨超三成
新浪港股 · 2025-12-15
昭衍新药午前涨超4% 本月股价已累计涨超三成
“天价猴”再临CRO，20cm大红柱吹响昭衍新药股价反攻号角？
智通财经网 · 2025-12-14
“天价猴”再临CRO，20cm大红柱吹响昭衍新药股价反攻号角？
异动快报：昭衍新药（603127）12月12日11点0分触及涨停板
证券之星 · 2025-12-12
异动快报：昭衍新药（603127）12月12日11点0分触及涨停板
CRO概念震荡走高 昭衍新药涨停
每日经济新闻 · 2025-12-12
CRO概念震荡走高 昭衍新药涨停
港股异动 | 昭衍新药(06127)再涨超11% 实验猴面临涨价、缺货 安评CRO有望迎边际改善
智通财经 · 2025-12-12
港股异动 | 昭衍新药(06127)再涨超11% 实验猴面临涨价、缺货 安评CRO有望迎边际改善
加载更多
公司概况
公司名称：
北京昭衍新药研究中心股份有限公司
所属行业：
研究和试验发展
上市日期：
2017-08-25
主营业务：
北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品是药物非临床研究服务、临床服务及其他、实验模型供应。
发行价格：
12.51
{"stockData":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":42.11,"timestamp":1767942000000,"preClose":42.18,"halted":0,"volume":22167871,"delay":0,"changeRate":-0.0017,"floatShares":630000000,"shares":749000000,"eps":0.3004,"marketStatus":"已收盘","change":-0.07,"latestTime":"01-09 15:00:00","open":41.92,"high":42.35,"low":40.72,"amount":919000000,"amplitude":0.0386,"askPrice":42.12,"askSize":32,"bidPrice":42.11,"bidSize":390,"shortable":0,"etf":0,"ttmEps":0.3004,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":5,"adr":0,"adjPreClose":42.18,"symbolType":"stock","openAndCloseTimeList":[[1767922200000,1767929400000],[1767934800000,1767942000000]],"highLimit":46.4,"lowLimit":37.96,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":749348220,"isCdr":false,"pbRate":3.89,"roa":"--","peRate":140.17976,"roe":"1.0%","epsLYR":0.1,"committee":0.246285,"marketValue":31555000000,"turnoverRate":0.0352,"status":1,"hkstockBrief":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":25.92,"timestamp":1767943178714,"preClose":24.22,"halted":0,"volume":8911119,"delay":0,"premium":"-44.88"},"floatMarketCap":26544000000},"requestUrl":"/m/hq/s/603127","defaultTab":"news","newsList":[{"id":"2602347895","title":"港股异动 | 昭衍新药(06127)涨超7% 近一月股价累涨近六成 公司有望受益猴价公允价值收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2602347895","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602347895?lang=zh_cn&edition=full","pubTime":"2026-01-09 14:49","pubTimestamp":1767941364,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药再涨超7%，近一月股价累涨近六成。截至发稿，涨7.02%，报25.92港元，成交额2.03亿港元。据方正证券测算，以昭衍新药为例，假设按照2024年实验猴均价计入公允价值8.49万/只，2025Q4价格提升至14万/只，假设猴场出栏率为17%，按照已知23200只猴测算，毛估计2025年新增公允价值约2.2亿。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","603127","BK1576","BK0216","BK1141"],"gpt_icon":0},{"id":"2601339124","title":"港股异动 | 昭衍新药(06127)再涨超4% 实验猴供需缺口或不断拉大 公司拥有优质稀缺实验猴资源","url":"https://stock-news.laohu8.com/highlight/detail?id=2601339124","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601339124?lang=zh_cn&edition=full","pubTime":"2026-01-08 10:59","pubTimestamp":1767841147,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药再涨超4%，截至发稿，涨3.36%，报24港元，成交额1.08亿港元。长江证券发布研报称，当前，实验猴供给端不断下降，需求端企稳回升以及新技术如小核酸、CAR-T 等大多也需要使用实验猴带来的结构化占比提升，实验猴供需缺口或正不断拉大，猴价也开始呈现上升趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","BK1576","BK0216","603127","BK1141"],"gpt_icon":0},{"id":"2601180738","title":"昭衍新药（603127）披露员工持股计划回购股份注销实施公告，1月6日股价下跌0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601180738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601180738?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:09","pubTimestamp":1767708560,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，昭衍新药报收于38.45元，较前一交易日下跌0.16%，最新总市值为288.17亿元。该股当日开盘39.8元，最高39.96元，最低37.8元，成交额达13.08亿元，换手率为5.37%。公司近日发布公告称，北京昭衍新药研究中心股份有限公司因终止实施2021年及2022年A股员工持股计划，拟注销回购专用账户中合计129,114股A股股份。该事项已履行董事会、股东大会审议程序，并完成债权人通知程序。本次注销股份将于2026年1月7日实施，公司总股本将由749,477,334股变更为749,348,220股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","06127","603127","BK0216","BK1141"],"gpt_icon":0},{"id":"2601002067","title":"昭衍新药（603127）披露H股及A股股本无变动情况，1月5日股价上涨10.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601002067","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601002067?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:42","pubTimestamp":1767606170,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，昭衍新药报收于38.51元，较前一交易日上涨10.0%，最新总市值为288.62亿元。公司近日发布公告称，北京昭衍新药研究中心股份有限公司已提交截至2025年12月31日的证券变动月报表。公告显示，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股于香港联交所上市，证券代码06127；A股于上海证券交易所上市，证券代码603127。已发行H股118,995,206股，A股627,179,094股，库存股3,303,034股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500025712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK0216","BK1141","159982","399300","603127","06127"],"gpt_icon":0},{"id":"2601797130","title":"异动快报：昭衍新药（603127）1月5日10点53分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2601797130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601797130?lang=zh_cn&edition=full","pubTime":"2026-01-05 10:55","pubTimestamp":1767581719,"startTime":"0","endTime":"0","summary":"证券之星1月5日盘中消息，10点53分昭衍新药触及涨停板。其所属行业医疗服务目前上涨。领涨股为三博脑科。该股为基因编辑，干细胞，AI医疗概念热股，当日基因编辑概念上涨4.47%，干细胞概念上涨4.05%，AI医疗概念上涨3.75%。12月31日的资金流向数据方面，主力资金净流出5814.26万元，占总成交额9.85%，游资资金净流入1665.91万元，占总成交额2.82%，散户资金净流入4148.35万元，占总成交额7.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500008901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","603127","BK1576","BK1141","BK0216"],"gpt_icon":0},{"id":"2601793240","title":"港股医药股走强 昭衍新药涨近10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601793240","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601793240?lang=zh_cn&edition=full","pubTime":"2026-01-05 10:24","pubTimestamp":1767579852,"startTime":"0","endTime":"0","summary":"南方财经1月5日电，港股医药股走强，截至发稿，昭衍新药(06127.HK)涨9.72%、泰格医药(03347.HK)涨5.94%、康龙化成(03759.HK)涨3.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601053608528139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","BK0216","BK1141","603127","06127","159718"],"gpt_icon":0},{"id":"2600842035","title":"每周股票复盘：昭衍新药（603127）实控人周志文拟减持不超1.99873%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600842035","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600842035?lang=zh_cn&edition=full","pubTime":"2026-01-02 01:23","pubTimestamp":1767288189,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，昭衍新药报收于36.94元，较上周的35.42元上涨4.29%。本周，昭衍新药12月25日盘中最高价报37.89元。12月22日盘中最低价报34.46元。昭衍新药当前最新总市值262.39亿元，在医疗服务板块市值排名6/51，在两市A股市值排名753/5181。减持原因为自身资金需求，减持价格将根据市场价格确定。本次减持不会导致公司控制权变更，且符合相关法律法规及此前承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","06127","BK1576","603127","BK1141"],"gpt_icon":0},{"id":"2595762310","title":"12月30日昭衍新药跌6.20%，广发小盘LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595762310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595762310?lang=zh_cn&edition=full","pubTime":"2025-12-30 15:32","pubTimestamp":1767079952,"startTime":"0","endTime":"0","summary":"证券之星消息，12月30日昭衍新药跌6.20%，收盘报34.8元，换手率5.23%，成交量33.0万手，成交额11.47亿元。重仓昭衍新药的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级5家，增持评级1家；过去90天内机构目标均价为40.13。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共19家，其中持有数量最多的公募基金为广发基金的广发小盘LOF。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000020196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1141","162703","603127","06127","BK0216"],"gpt_icon":0},{"id":"2595662547","title":"港股创新药板块午后持续走弱，昭衍新药跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595662547","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595662547?lang=zh_cn&edition=full","pubTime":"2025-12-30 13:15","pubTimestamp":1767071744,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月30日，港股创新药板块午后持续走弱，昭衍新药跌超7%，荣昌生物、康龙化成、歌礼制药-B跌超5%，凯莱英、诺诚健华跟跌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512303605538957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605538957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK0216","BK1574","06127","BK1576","603127","BK1141","06978","159992"],"gpt_icon":0},{"id":"2595678941","title":"昭衍新药实控人之一周志文计划减持不超近2%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2595678941","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595678941?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:50","pubTimestamp":1767001821,"startTime":"0","endTime":"0","summary":"12月29日，昭衍新药（603127/06127）发布公告，实际控制人之一周志文因自身资金需求，计划自2026年1月22日至2026年4月21日，通过集中竞价和大宗交易方式减持不超过1498万股，占公司总股本的1.99873%。2025年前三季度，昭衍新药实现收入9.85亿元，归母净利润8071万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512293604528115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","BK1576","BK0216","06127","603127"],"gpt_icon":0},{"id":"2594823703","title":"“顶流”刘格菘年内两度卸任 广发主动权益基金三年业绩之殇","url":"https://stock-news.laohu8.com/highlight/detail?id=2594823703","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594823703?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:13","pubTimestamp":1766671980,"startTime":"0","endTime":"0","summary":" 截至12月24日，广发小盘成长近三年的收益率仅有3.36%。 12月24日，基金经理刘格菘卸任其管理年限最长的广发小盘成长，年内已两度退出在管产品。 纵观广发基金，截至12月24日，在131只成立超过3年的主动权益类产品中，近三年业绩为负的产品达45只，有90只产品跑输业绩比较基准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjyj/2025-12-25/doc-inhcztfx4620167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002028","BK0083","LU2289578879.USD","BK0216","SGXZ81163826.USD","688256","BK0132","IE00BYTNYN87.SGD","LU1997245094.SGD","BK0078","BK0077","BK0214","600562","LU2778985437.USD","BK0224","688385","SG9999001069.SGD","BK0028","BK0024","LU1969619763.USD","302132","SG9999006597.SGD","300857","IE00B5MMRT66.SGD","LU2476274720.SGD","LU1255011170.USD","BK0149","BK0094","BK0062","BK0258","SGXZ90724238.SGD","LU1146622755.USD","SG9999001093.SGD","603127","SG9999011746.SGD","BK0188","300113","BK0231","LU1997244956.HKD","LU2328871848.SGD","SG9999003461.SGD","BK0108","LU2495084118.USD","SGXZ49509284.SGD","002683","SG9999001051.SGD","BK0156","603678","LU2476274308.USD","SG9999002950.SGD"],"gpt_icon":0},{"id":"2593945005","title":"港股异动 | 昭衍新药(06127)涨超5% 上游实验猴供给端紧张 公允价值变动有望贡献利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2593945005","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593945005?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:43","pubTimestamp":1766457795,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药涨超5%，截至发稿，涨5.17%，报22.38港元，成交额1.16亿港元。消息面上，国海证券12月22日研报指出，临床前CRO客户需求回暖，上游实验猴供给端紧张。据方正证券测算，以昭衍新药为例，假设按照2024年实验猴均价计入公允价值8.49万/只，2025Q4价格提升至14万/只，假设猴场出栏率为17%，按照已知23200只猴测算，毛估计2025年新增公允价值约2.2亿。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BK1141","603127","06127","BK1576"],"gpt_icon":0},{"id":"2593710420","title":"港股异动 | CRO概念股承压走低 康龙化成(03759)跌超4% 昭衍新药(06127)跌超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593710420","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593710420?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:24","pubTimestamp":1766388287,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股承压走低，截至发稿，康龙化成跌4.32%，报21.24港元；昭衍新药跌3.29%，报21.16港元；凯莱英跌2.31%，报78.15港元；维亚生物跌1.98%，报1.98港元。信达证券指，过去两年《生物安全法案》是压制CXO板块估值的重要原因，和最初版本相比，最终落地的版本没有点名具体企业，整体相对温和。虑到美联储已经进入降息通道，全球生物医药投融资有望边际改善，随着法案落地，CXO板块有望迎来业绩和估值的双重修复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","01873","03759","BK0216","BK1191","BK1576","300759","BK1141","06821","603127"],"gpt_icon":0},{"id":"2592163639","title":"昭衍新药：公司具备OECD的GLP认证资质","url":"https://stock-news.laohu8.com/highlight/detail?id=2592163639","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592163639?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:10","pubTimestamp":1765980600,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月17日，昭衍新药在互动平台回答投资者提问时表示，公司具备OECD的GLP认证资质，可以承接相关项目。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-17/doc-inhccnef9221279.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-17/doc-inhccnef9221279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","BK1576","GLP","BK1141","603127","BK4590","BK4144","06127"],"gpt_icon":0},{"id":"2592495423","title":"港股异动 | 昭衍新药(06127)涨超8% 实验猴价格近期上行 机构料供需偏紧状态或将维持","url":"https://stock-news.laohu8.com/highlight/detail?id=2592495423","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592495423?lang=zh_cn&edition=full","pubTime":"2025-12-17 09:39","pubTimestamp":1765935593,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药涨超8%，截至发稿，涨8.21%，报22.14港元，成交额3986.2万港元。方正证券12月15日发布的研报指出，实验猴作为临床前安评的刚性资源，随着临床前CRO订单稳步回暖，需求提升；且供给侧短期扩产难度较大，部分猴场表示产能已预定至2026年一季度，预计供需偏紧状态或将维持，短期价格有望进一步上行。方正证券认为，头部CRO战略资源储备丰富，有望受益于行业回暖+猴价公允价值收益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382410.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","603127","BK1576","BK0216","BK1141"],"gpt_icon":0},{"id":"2591269466","title":"昭衍新药午前涨超4% 本月股价已累计涨超三成","url":"https://stock-news.laohu8.com/highlight/detail?id=2591269466","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591269466?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:59","pubTimestamp":1765771140,"startTime":"0","endTime":"0","summary":" 昭衍新药午前涨超4%，本月股价已累计涨超三成。截至发稿，股价上涨4.23%，报22.18港元，成交额2.11亿港元。 根据北京商报，12月9日实验猴价格呈加速上涨趋势，大约14万元/只。 据方正证券测算，以昭衍新药为例，假设按照2024年实验猴均价计入公允价值8.49万/只，2025Q4价格提升至14万/只，假设猴场出栏率为17%，按照已知23200只猴测算，毛估计2025年新增公允价值约2.2亿。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-12-15/doc-inhawauf3941208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06127","BK1576","BK1141","603127","BK0216"],"gpt_icon":0},{"id":"2591637009","title":"“天价猴”再临CRO，20cm大红柱吹响昭衍新药股价反攻号角？","url":"https://stock-news.laohu8.com/highlight/detail?id=2591637009","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591637009?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:30","pubTimestamp":1765672226,"startTime":"0","endTime":"0","summary":"在股价阴跌了4个多月后，昭衍新药靠着一根“20cm大红柱”将市场目光重新拉回到这家安评龙头以及近期再度暴涨的“猴价”上。但实际上，昭衍新药此次股价新高之路并不平坦。12月12日一根“20cm大红柱”则将昭衍新药收盘价拉至21.25港元，也让筹码获利比例从12月11日的32.02%大幅升至12月12日的78.84%。从最新的Q3财报来看，2025年前三季度，昭衍新药新签订单金额达16.4亿元，同比增长17.1%，其中第三季度增速达24%，已出现回暖迹象。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381223.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1141","BK0216","BK1576","06127","603127"],"gpt_icon":0},{"id":"2590521874","title":"异动快报：昭衍新药（603127）12月12日11点0分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2590521874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590521874?lang=zh_cn&edition=full","pubTime":"2025-12-12 11:05","pubTimestamp":1765508724,"startTime":"0","endTime":"0","summary":"证券之星12月12日盘中消息，11点0分昭衍新药触及涨停板。其所属行业医疗服务目前上涨。该股为干细胞，基因编辑，CAR-T疗法概念热股，当日干细胞概念上涨0.88%，基因编辑概念上涨0.87%，CAR-T疗法概念上涨0.34%。12月11日的资金流向数据方面，主力资金净流入7207.58万元，占总成交额6.85%，游资资金净流出1712.76万元，占总成交额1.63%，散户资金净流出5494.82万元，占总成交额5.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200011950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK0216","BK1576","06127","603127"],"gpt_icon":0},{"id":"2590864522","title":"CRO概念震荡走高 昭衍新药涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2590864522","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590864522?lang=zh_cn&edition=full","pubTime":"2025-12-12 10:59","pubTimestamp":1765508340,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月12日，CRO概念盘中震荡走高，昭衍新药涨停，益诺思涨近10%，美迪西、博腾股份、康龙化成、阳光诺和跟涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-12/doc-inhapfim7328287.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-12/doc-inhapfim7328287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1576","BK0216","603127","06127","BK1141"],"gpt_icon":0},{"id":"2590809526","title":"港股异动 | 昭衍新药(06127)再涨超11% 实验猴面临涨价、缺货 安评CRO有望迎边际改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2590809526","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590809526?lang=zh_cn&edition=full","pubTime":"2025-12-12 10:01","pubTimestamp":1765504888,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药再涨超11%，截至发稿，涨11.42%，报19.8港元，成交额1.29亿港元。消息面上，12月上旬，食蟹猴单价悄然跃过10万元大关。据红星资本局调查，从广东、广西、云南等地多家实验猴养殖企业了解到，食蟹猴出现了供应短缺的现象，身价已涨至12、13万元。华泰证券认为，昭衍新药是国内非临床安全性评价领域龙头，以过硬的服务能力持续提升海内外市场影响力。实验猴价格上升、新签订单回暖等或为后续主要催化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e9a0af42f55527cb14733ed30e19bd7f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","06127","BK1576","603127","BK1141"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767943196671,"stockEarnings":[{"period":"1week","weight":0.2048},{"period":"1month","weight":0.4079},{"period":"3month","weight":0.2516},{"period":"6month","weight":0.6225},{"period":"1year","weight":1.6518},{"period":"ytd","weight":0.2048}],"compareEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":0.0444},{"period":"3month","weight":0.0477},{"period":"6month","weight":0.1632},{"period":"1year","weight":0.264},{"period":"ytd","weight":0.0288}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京昭衍新药研究中心股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2017-08-25","address":"北京市大兴区北京经济技术开发区荣京东街甲5号","registeredCapital":"74934万元","survey":" 北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品是药物非临床研究服务、临床服务及其他、实验模型供应。","listedPrice":12.51},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,603127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}